[PharmaEssentia] Announcement of the Board of Directors' Approval of the Q1 2026 Consolidated Financial Report

1. Date of report to the Board of Directors or resolution by the Board of Directors: 2026/05/13 2. Date of approval by the Audit Committee: 2026/05/13 3. Reporting period of financial report or annual self-reported financial information: 2026/01/01~2026/03/31 4. Cumulative operating revenue from January 1 to the current period (in thousands of NTD): 5,121,378 5. Cumulative operating gross profit (gross loss) from January 1 to the current period (in thousands of NTD): 4,500,097 6. Cumulative operating income (loss) from January 1 to the current period (in thousands of NTD): 2,087,077 7. Cumulative pre-tax net profit (net loss) from January 1 to the current period (in thousands of NTD): 2,335,581 8. Cumulative net profit (net loss) for the current period from January 1 to the current period (in thousands of NTD): 2,149,627 9. Cumulative net profit (net loss) attributable to owners of the parent from January 1 to the current period (in thousands of NTD): 2,149,627 10. Cumulative basic earnings per share (loss) from January 1 to the current period (in NTD): 5.79 11. Total assets at period-end (in thousands of NTD): 40,089,669 12. Total liabilities at period-end (in thousands of NTD): 5,635,458 13. Equity attributable to owners of the parent at period-end (in thousands of NTD): 34,454,211 14. Other matters that should be specified: None.